Reporting Manager
Paradigm BioCapital Advisors LP
Symbol
EWTX
Shares outstanding
105,503,387 shares
Disclosed Ownership
6,541,210 shares
Ownership
6.2%
Form type
SCHEDULE 13G/A
Filing time
17 Feb 2026, 16:02:54 UTC
Date of event
31 Dec 2025
Previous filing
03 Feb 2025

Quoteable Key Fact

"Paradigm Biocapital Advisors LP disclosed 6.2% ownership in Edgewise Therapeutics, Inc. Common Stock, $0.0001 par value per share (EWTX) on 31 Dec 2025."

Quick Takeaways

  • Paradigm Biocapital Advisors LP filed SCHEDULE 13G/A for Edgewise Therapeutics, Inc. Common Stock, $0.0001 par value per share (EWTX).
  • Disclosed ownership: 6.2%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 03 Feb 2025.
  • Current filing was accepted on 17 Feb 2026, 16:02.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Paradigm BioCapital Advisors LP 6.2% 6,541,210 6,541,210 0 /s/ David K. Kim David K. Kim / Authorized Signatory
Paradigm BioCapital Advisors GP LLC 6.2% 6,541,210 6,541,210 0 /s/ David K. Kim David K. Kim / Authorized Signatory
Senai Asefaw, M.D. 6.2% 6,541,210 6,541,210 0 /s/ Senai Asefaw, M.D. N/A
Paradigm BioCapital International Fund Ltd. 5.5% 5,778,924 5,778,924 0 /s/ David K. Kim David K. Kim / Authorized Signatory
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .